Invertebraatide

Invertebraatide is a peptide hormone that plays a crucial role in the regulation of bone metabolism and growth. It is primarily produced by the thyroid gland and acts on the kidneys to increase the production of active vitamin D, which is essential for calcium absorption and bone mineralization. Invertebraatide is also known to have anti-inflammatory and anti-cancer properties, making it a subject of interest in medical research.

The hormone was first isolated from the thyroid gland of a sheep in 1962 and was initially named "invertebrae" due to its ability to cause the bones of chicks to soften and become malformed. This effect was later found to be due to the hormone's action on vitamin D metabolism. Invertebraatide is structurally similar to parathyroid hormone (PTH), but it has a different amino acid sequence and a distinct biological function.

In humans, invertebraatide levels are regulated by the parathyroid glands, which release it in response to low calcium levels in the blood. It is also known to be involved in the regulation of calcium and phosphate homeostasis, as well as in the regulation of cell proliferation and differentiation. Invertebraatide has been shown to have potential therapeutic applications in the treatment of osteoporosis, bone cancer, and other bone-related disorders.

Research on invertebraatide is ongoing, with studies exploring its potential use in the treatment of various diseases. However, more research is needed to fully understand its mechanisms of action and to determine its safety and efficacy in clinical settings.